Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Gliosarcoma 1Glioblastoma 1Gallbladder Neoplasms 1Central Nervous System Neoplasms 1Brain Neoplasms 1Bile Duct Neoplasms 1Astrocytoma 1

Interventions

Specimen Handling 5Oxaliplatin 5Leucovorin 5Magnetic Resonance Spectroscopy 4Fluorouracil 4Erlotinib Hydrochloride 4Biopsy 4Trastuzumab 3Capecitabine 3dehydroftorafur 2cobimetinib 2atezolizumab 2Sorafenib 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2MK 2206 2Lapatinib 2Interleukin-12 Subunit p35 2Gemcitabine 2Chemotherapy, Adjuvant 2varlilumab 1trametinib 1tipifarnib 1sargramostim 1peposertib 1pembrolizumab 1motexafin lutetium 1ixabepilone 1entinostat 1cediranib 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Gallbladder Neoplasms × Dihematoporphyrin Ether × Clear all
NCT00253617 2013-04-04

Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 3 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡